Clinical and laboratory features at the time of diagnosis in patients with MDS classified according to the WHO subtypes
| . | MDS (all patients) . | RA . | 5q . | RARS . | RC + Dys . | RAEB . | RAEB I . | RAEB II . | MDS unclass . |
|---|---|---|---|---|---|---|---|---|---|
| Patients = N (%) | 281 | 43 (15) | 1 (0.5) | 4 (1.5) | 91 (32) | 92 (33) | 50 (18) | 42 (15) | 50 (18) |
| Median age, y (range) | 73 (31-92) | 71 (51-86) | 31 | 74 (49-75) | 76 (44-92) | 74 (39-89) | 72 (39-83) | 75 (43-89) | 70 (39-88) |
| Sex ratio (M/F) | 0.74:1 | 0.95:1 | 1:1 | 0.60:1 | 0.88:1 | 0.86:1 | 0.89:1 | 0.61:1 | |
| Neutrophils × 109/μL (median; range) | 2.1 (0.1-21.1) | 2.5 (0.5-13.4) | 5.5 | 2.6 (1.7-4.6) | 2.4 (0.3-15.1) | 1.5 (0.1-21.1) | 1.6 (0.1-21.1) | 1.6 (0.2-16.0) | 2.1 (0.1-9.5) |
| Hemoglobin g/dL (median; range) | 9.4 (3.6-15.1) | 9.8 (5.9-13.1) | 3.6 | 10.3 (8.0-11.4) | 10.0 (5.2-14.7) | 9.4 (4.8-15.1) | 9.4 (4.8-13.3) | 9.3 (6.1-15.1) | 8.6 (3.8-13.4) |
| Platelets × 109/μL (median; range) | 137 (4-763) | 151 (13-433) | 414 | 298 (59-597) | 185 (4-403) | 104 (5-763) | 110 (5-763) | 106 (11-603) | 151 (10-494) |
| LDH (120-240 U/L) (median; range) | 210 (102-990) | 221 (111-512) | 143 | 181 (140-188) | 199 (102-990) | 213 (116-816) | 201 (116-645) | 221 (121-816) | 240 (105-952) |
| Bone marrow blasts (%) | 2 (0-20) | 1 (0-4) | 0 | 1 (0-2) | 1 (0-4) | 10 (5-20) | 8 (5-10) | 17 (11-20) | 1 (0-4) |
| Available cytogenetics = N (%) | 172 (61) | 25 (48) | 1 (100) | 2 (50) | 59 (65) | 67 (73) | 36 (72) | 31 (74) | 18 (36) |
| Normal karyotype (%) | 47 | 66 | 0 | 100 | 46 | 48 | 49 | 47 | 39 |
| IPSS (% patients) | |||||||||
| Low | 31 | 52 | 100 | 100 | 48 | 0 | 0 | 0 | 33 |
| Intermediate-1 | 45 | 39 | 0 | 50 | 37 | 67 | 0 | 67 | |
| Intermediate-2 | 19 | 9 | 0 | 2 | 48 | 33 | 67 | 0 | |
| High | 5 | 0 | 0 | 0 | 15 | 0 | 33 | 0 | |
| Median survival (mo) | 43 | 66 | (NR) | (65) | 86 | 15 | 18 | 12 | 67 |
| Transition to AML (%) | 28 | 26 | 11 | 38 | 28 | 52 | 44 | ||
| Median preleukemic duration (mo) | 136 | 203 | (NR) | (NR) | NR | 24 | 28 | 11 | 101 |
| . | MDS (all patients) . | RA . | 5q . | RARS . | RC + Dys . | RAEB . | RAEB I . | RAEB II . | MDS unclass . |
|---|---|---|---|---|---|---|---|---|---|
| Patients = N (%) | 281 | 43 (15) | 1 (0.5) | 4 (1.5) | 91 (32) | 92 (33) | 50 (18) | 42 (15) | 50 (18) |
| Median age, y (range) | 73 (31-92) | 71 (51-86) | 31 | 74 (49-75) | 76 (44-92) | 74 (39-89) | 72 (39-83) | 75 (43-89) | 70 (39-88) |
| Sex ratio (M/F) | 0.74:1 | 0.95:1 | 1:1 | 0.60:1 | 0.88:1 | 0.86:1 | 0.89:1 | 0.61:1 | |
| Neutrophils × 109/μL (median; range) | 2.1 (0.1-21.1) | 2.5 (0.5-13.4) | 5.5 | 2.6 (1.7-4.6) | 2.4 (0.3-15.1) | 1.5 (0.1-21.1) | 1.6 (0.1-21.1) | 1.6 (0.2-16.0) | 2.1 (0.1-9.5) |
| Hemoglobin g/dL (median; range) | 9.4 (3.6-15.1) | 9.8 (5.9-13.1) | 3.6 | 10.3 (8.0-11.4) | 10.0 (5.2-14.7) | 9.4 (4.8-15.1) | 9.4 (4.8-13.3) | 9.3 (6.1-15.1) | 8.6 (3.8-13.4) |
| Platelets × 109/μL (median; range) | 137 (4-763) | 151 (13-433) | 414 | 298 (59-597) | 185 (4-403) | 104 (5-763) | 110 (5-763) | 106 (11-603) | 151 (10-494) |
| LDH (120-240 U/L) (median; range) | 210 (102-990) | 221 (111-512) | 143 | 181 (140-188) | 199 (102-990) | 213 (116-816) | 201 (116-645) | 221 (121-816) | 240 (105-952) |
| Bone marrow blasts (%) | 2 (0-20) | 1 (0-4) | 0 | 1 (0-2) | 1 (0-4) | 10 (5-20) | 8 (5-10) | 17 (11-20) | 1 (0-4) |
| Available cytogenetics = N (%) | 172 (61) | 25 (48) | 1 (100) | 2 (50) | 59 (65) | 67 (73) | 36 (72) | 31 (74) | 18 (36) |
| Normal karyotype (%) | 47 | 66 | 0 | 100 | 46 | 48 | 49 | 47 | 39 |
| IPSS (% patients) | |||||||||
| Low | 31 | 52 | 100 | 100 | 48 | 0 | 0 | 0 | 33 |
| Intermediate-1 | 45 | 39 | 0 | 50 | 37 | 67 | 0 | 67 | |
| Intermediate-2 | 19 | 9 | 0 | 2 | 48 | 33 | 67 | 0 | |
| High | 5 | 0 | 0 | 0 | 15 | 0 | 33 | 0 | |
| Median survival (mo) | 43 | 66 | (NR) | (65) | 86 | 15 | 18 | 12 | 67 |
| Transition to AML (%) | 28 | 26 | 11 | 38 | 28 | 52 | 44 | ||
| Median preleukemic duration (mo) | 136 | 203 | (NR) | (NR) | NR | 24 | 28 | 11 | 101 |
LDH, lactate dehydrogenase; NR, not reached.